Form 8-K REGENERON PHARMACEUTICAL For: Oct 31
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/21/2026
- Wall St indexes advance with boost from chips, Iran optimism
- Intel soars after Trump says Apple agreed to work with chipmaker on US production
- Apple CEO warns price hikes 'unavoidable' as chip costs bite - WSJ
- Wall Street scrambles to lift Micron price targets ahead of earnings
- SanDisk and Micron surge as Apple confirms memory price pass-through
- Zelenskiy: best guarantee of Europe's future is fast-track EU membership for Ukraine
- Needham Starts NeoVolta (NEOV) at Buy
- CoreWeave trains DeepSeek-V3 in two minutes in MLPerf benchmark
- Companies to add 40 million barrels of oil to US SPR after Iran war ends, energy secretary says
- Tesla acquires AI hardware company for up to $2 billion in stock
Regeneron Pharma (REGN) PT Lowered to $880 at Leerink Partners
November 1, 2024 7:19 AM EDTLeerink Partners analyst Andrew Berens lowered the price target on Regeneron Pharma (NASDAQ: REGN) to $880.00 (from $1,077.00) while maintaining a Market Perform rating.
The analyst comments "Bottom Line: We are reducing our REGN PT from $1,077 (22x old 2025E EPS of $48.96) to $880 (20x new 2025E EPS of $44.01). We... More
Regeneron Pharma (REGN) PT Lowered to $1,170 at Evercore ISI
October 31, 2024 4:35 PM EDTEvercore ISI analyst Cory Kasimov lowered the price target on Regeneron Pharma (NASDAQ: REGN) to $1,170.00 (from $1,175.00) while maintaining a Outperform rating.
The analyst comments "Its been all tricks and no treats for REGN. Following todays 3Q print, shares are off another ~10%... More
